Strides Pharma Science Ltd
Strides Pharma Science Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Strides aims to grow its U.S. The company reported a phenomenal year in FY '25 with highest ever PAT on an operating basis.
From Strides Pharma Science Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strides aims to grow its U.S. business from $291 million to $400 million in revenue, focusing on measured product launches rather than rapid acceleration.
- Out of a 60-product library identified for re-launch in the U.S., not all will be launched; launches are carefully timed to control growth sustainably.
- Average revenue per product launch has increased from about $3 million three years ago to $5 million currently, with several products exceeding $20 million.
- Beyond the $400 million U.S. target, new growth will be driven by internal R&D, including 505(b)(2) filings expected at 3-4 products per year.
- Other regulated markets are expected to mirror U.S. growth and could reach size parity within 4-5 years, driven by portfolio expansion and new customer acquisitions.
2 more points from Strides Pharma Science Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Recent capex of INR350 crores over the last 2 years focused on debottlenecking and increasing capacities.
- For FY '26, capex expected to be much lower than INR245 crores spent in the previous year.
- Future capital allocation is shifting towards increased R&D spend, especially for the Beyond $400 million U.S. portfolio.
- R&D spend is almost doubling, with about $15 million of the $20 million targeted for beyond $400 million strategy.
- No plans for major new capex; focus on measured launches and technology-driven capacity enhancements.
2 more points from Strides Pharma Science Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Strides Pharma Science Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Strides Pharma Science Ltd Q4 FY25 results?
Strides aims to grow its U.S. The company reported a phenomenal year in FY '25 with highest ever PAT on an operating basis.
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Recent capex of INR350 crores over the last 2 years focused on debottlenecking and increasing capacities. - For FY '26, capex expected to be much lower than INR245 crores spent in the previous year. - Future capital allocation is shifting towards increased R&D spend, especially for the Beyond $400 million U.S.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.